Synergy IMT creates therapeutics with the potential to treat a broad range of cancer and non-cancer diseases including neurodegenerative and viral. 

SYN120 is a DiAx drug conjugate. DiAx is a proprietary small single chain antibody-based format that is well suited for for manufacturing a site-specific cytotoxic drug conjugation. SYN120 targets a novel tumor antigen that is selected for elimination of tumor cells and inhibition of tumorigenesis and metastasis. 

SYN220 is a multispecific that targets a universal tumor antigen - immune checkpoint and a TNFSF receptor. Multispecifc therapeutic candidates are developed to stimulate immune cells to induce a durable anti-tumor response. SYN120 induces potent, tumor antigen-dependent, immune cell signaling and tumor cell cytotoxicity.

SYN320   is a multivalent agonist designed to modify pathogenic processes in neurodegenerative diseases including Alzheimer's Disease.